Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699305 · ClinicalTrials.gov registry record
Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers
A clinical trial of Cutaneous Wounds, sponsored by RedDress.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04699305: Recruiting study of Cutaneous Wounds, sponsored by RedDress.
NCT04699305 is a study of Cutaneous Wounds that is actively recruiting participants, run by RedDress. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04699305, a study of Cutaneous Wounds, is actively recruiting participants, sponsored by RedDress.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.
Primary Outcome
Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).
Conditions Studied
Interventions
- DEVICE ActiGraft
Study Locations (1)
Nevada
- Wound Care Experts - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2027-01-31 |
What NCT04699305 shows while recruiting
NCT04699305 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Cutaneous Wounds appearing as the primary indexed condition, and to 1 intervention - of which ActiGraft is the first listed.
NCT04699305 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT04699305 about?
NCT04699305 is a clinical study titled "Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers". Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.
What is the current status of trial NCT04699305?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-02-14. Estimated completion is 2027-01-31.
What conditions does trial NCT04699305 study?
This clinical trial studies the following conditions: Cutaneous Wounds.
What interventions are being tested in trial NCT04699305?
The interventions under investigation include: ActiGraft (DEVICE).
Who is sponsoring clinical trial NCT04699305?
This trial is sponsored by RedDress, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699305 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI